^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gallbladder Cancer
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Neoadjuvant therapy (for gallbladder cancer only)…Other recommended regimens…single agents…Gemcitabine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2020
    Title:

    55P - Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies

    Published date:
    09/19/2020
    Excerpt:
    Non-Supportive evidence: While gemcitabine-based chemotherapy (GBCT) is the first-line standard of care for patients with...21.7%; gallbladder carcinoma…this pooled analysis of BCAT and PRODIGE 12 did not show any improvement in RFS or OS. GBCT should not be used as an adjuvant treatment for BTC.
    Trial ID:
    2008-004560-39